Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target [...] The post Takeda signs US$600M AI drug discovery deal with Insilico appeared first on AI News.